First‐line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation‐positive non‐small cell lung cancer

First‐line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation‐positive non‐small cell lung cancer

Abstract Background Few studies have compared the efficacy of the irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI), afatinib, with that of reversible EGFR‐TKIs. Therefore, this study assessed the effectiveness of afatinib, erlotinib, and gefitinib in terms of OS (ov...

Full description

Bibliographic Details
Main Authors: Po‐Lan Su, Chian‐Wei Chen, Yi‐Lin Wu, Chien‐Chung Lin, Wu‐Chou Su
Format: Article
Language:English
Published: Wiley 2021-02-01
Series:Thoracic Cancer
Subjects:
EGFR‐TKI
non‐small cell lung cancer
progression‐free survival
Online Access:https://doi.org/10.1111/1759-7714.13462

Internet

https://doi.org/10.1111/1759-7714.13462

Similar Items